Similarly, Glycogen synthase kinase 3 (GSK3), a serine-threonine kinase, was identified as a putative regulator of TFEB activity in 2011 and was found to play a role in AD pathogenesis by phosphorylating APP and tau to promote Aβ42 production (Settembre et al., 2011; Reddy, 2013). The gene discussed is MAPT; the disease is Alzheimer disease.